Table 2.
Mean 24-h average pain scores
| Visit | Treatment received during the double-blind phase* | Total (N = 474) | |
|---|---|---|---|
| OXN PR (N = 239) | Oxy PR (N = 235) | ||
| Visit 9† (Day 1) | |||
| n | 238 | 234 | 472 |
| Mean (SD) | 3.5 (1.65) | 3.6 (1.64) | 3.6 (1.65) |
| Visit 10 (Day 7 ± 3 days) | |||
| n | 233 | 224 | 457 |
| Mean (SD) | 3.5 (1.77) | 3.6 (1.60) | 3.5 (1.69) |
| Visit 11 (Day 30 ± 7 days) | |||
| n | 229 | 223 | 452 |
| Mean (SD) | 3.5 (1.80) | 3.4 (1.69) | 3.4 (1.74) |
| Visit 12 (Day 90 ± 7 days) | |||
| n | 219 | 207 | 426 |
| Mean (SD) | 3.6 (1.91) | 3.4 (1.65) | 3.5 (1.79) |
| Visit 13 (Day 180 ± 7 days) | |||
| n | 211 | 205 | 416 |
| Mean (SD) | 3.6 (1.86) | 3.6 (1.66) | 3.6 (1.76) |
| Visit 14 (Day 270 ± 7 days) | |||
| n | 205 | 201 | 406 |
| Mean (SD) | 3.5 (1.78) | 3.5 (1.78) | 3.5 (1.78) |
| Visit 15‡ (Day 360 ± 7 days) | |||
| n | 234 | 228 | 462 |
| Mean (SD) | 3.5 (1.96) | 3.6 (1.96) | 3.6 (1.96) |
*
Days refer to number of days of OXN PR treatment during the extension phases only (excluding double-blind treatment). SD, standard deviation. *Scores for the total population and scores subgrouped according to treatment patients received during the double-blind phases of the studies.
†
Pain scores were not reported by two patients at Visit 9. Visit 9 was likely to be the same day as Visit 8, the end of double-blind assessment.
‡
LOCF.